- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Prepulsid® | Propulsid®
cisapride is an approved drug (FDA (1993))
Compound class: Synthetic organic
Comment: Cisapride is an enantioneric mixture and we show the non-stereoisomeric structure here to represent the mixture. One stereoisomeric structure is shown by CHEMBL560739.
Cisapride must be used with caution due to reports of drug-induced arrhythmias and long QT syndrome. Although this drug was originally given marketing approval by the US FDA in 1993, all registered formulations have since been discontinued. In the EU (since 2002) conditions of use have been applied to active marketing authorisations for cisapride containing medicinal products.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|Cisapride is used to treat motility related gastrointestinal disorders such as gastroesophageal reflux disease.|
|Mechanism Of Action and Pharmacodynamic Effects|
|Cisapride is a serotonin 4 (5-HT4) receptor agonist which increases acetylcholine release, resulting in a combination of effects which culminate in accelerated gastric emptying and intestinal transit (eg increased tone and amplitude of gastric contractions, relaxation of the pyloric sphincter, increased duodenal and jejunal peristalsis).|